Hims & Hers: Sharp Correction After the end of the FDA Exception and Cigna Offensive

Regulatory changes and new pricing strategies are slowing down the rise of the telemedicine stock Competition from insurers is increasing After a strong run on the stock of the telemedicine provider Hims & Hers Health (Ticker: HIMS), which has been fueled since the beginning of the year by growth fantasies surrounding digital healthcare and GLP-1 medications as well as an extremely high short-seller ratio, a sharp correction is now in sight. On May 21, 2025, the stock of Hims & Hers Health (Ticker: HIMS) saw a significant decline,...